[
  {
    "ts": "2025-06-26T10:55:00+00:00",
    "headline": "Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia. Presbyopia is the progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain, particularly in dim lighting conditions.",
    "url": "https://finance.yahoo.com/news/viatris-announces-positive-top-line-105500487.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "79424939-8750-30d4-8855-872ee4d0ac94",
      "content": {
        "id": "79424939-8750-30d4-8855-872ee4d0ac94",
        "contentType": "STORY",
        "title": "Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia",
        "description": "",
        "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia. Presbyopia is the progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain, particularly in dim lighting conditions.",
        "pubDate": "2025-06-26T10:55:00Z",
        "displayTime": "2025-06-26T10:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "Viatris OUS Logo (PRNewsfoto/Viatris Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q8X7v9Q2NGJ8HikeN5BEPA--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g4h5fNpHKz3PzdbDqFxRYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-announces-positive-top-line-105500487.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-announces-positive-top-line-105500487.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-26T10:00:00+00:00",
    "headline": "Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA",
    "summary": "Theravance Biopharma, Inc. (\"Theravance Biopharma\" or the \"Company\") (NASDAQ: TBPH) today announced that Viatris Inc. (\"Viatris\"), has secured regulatory approval from China's National Medical Products Administration (NMPA) for YUPELRI® (revefenacin) inhalation solution, the first once–daily nebulized long–acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in China.",
    "url": "https://finance.yahoo.com/news/theravance-biopharma-announces-approval-yupelri-100000193.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "35268f37-41a6-3a76-a3fd-cdc489f65bc0",
      "content": {
        "id": "35268f37-41a6-3a76-a3fd-cdc489f65bc0",
        "contentType": "STORY",
        "title": "Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA",
        "description": "",
        "summary": "Theravance Biopharma, Inc. (\"Theravance Biopharma\" or the \"Company\") (NASDAQ: TBPH) today announced that Viatris Inc. (\"Viatris\"), has secured regulatory approval from China's National Medical Products Administration (NMPA) for YUPELRI® (revefenacin) inhalation solution, the first once–daily nebulized long–acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in China.",
        "pubDate": "2025-06-26T10:00:00Z",
        "displayTime": "2025-06-26T10:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/4d2df003249986704ef2ebec0198a9bd",
          "originalWidth": 400,
          "originalHeight": 94,
          "caption": "Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Zw4NV68rMRvlpqNZmWt3g--~B/aD05NDt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/4d2df003249986704ef2ebec0198a9bd.cf.webp",
              "width": 400,
              "height": 94,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gH9X89obSKBSOKrYcKKxrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4d2df003249986704ef2ebec0198a9bd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/theravance-biopharma-announces-approval-yupelri-100000193.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/theravance-biopharma-announces-approval-yupelri-100000193.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TBPH"
            },
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]